secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001193125-25-098599
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

IN8bio Announces Preclinical Data from Gamma-Delta T Cell Engager Platform at AACR 2025
--------------------------------------------------------------------------------

- INB-619 (CD19) and INB-633 (CD33) showed potent dose-related killing of leukemia cells at low picomolar concentrations in preclinical studies.
- Platform activated and expanded both Vδ1+ and Vδ2+ T cell subsets, addressing reduced cell counts in cancer patients.
- Minimal secretion of cytokines IL-6, IL-10, IL-17a suggests lower risk of cytokine release syndrome versus conventional CD3 TCEs.
- CEO William Ho highlighted potential for off-the-shelf, scalable platform to target cancers and autoimmune diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525098599/0001193125-25-098599-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000119312525098599/d788811d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-098599

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer